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Enabling next-generation antibody-based photodynamic 
therapeutics  
Antoine Maruani,a Huguette Savoie,b Francesca Bryden,b Stephen Caddick,a Ross Boyle*b and Vijay 
Chudasama*a
Herein we present a significant step towards next-generation 
antibody-based photodynamic therapeutics. Site-selective 
modification of a clinically relevant monoclonal antibody, with a 
serum-stable linker bearing a strained alkyne, allows for the 
controlled Cu-free “click” assembly of an in vitro active antibody-
based PDT agent using a water soluble azide porpyhrin. 
Targeted photodynamic therapy (PDT) directed by 
macromolecules is based on the conjugation of a non-toxic 
photosensitizer to a biomolecule that has an ability to 
discriminate between different cell types.1 The use of 
monoclonal antibodies for the targeted delivery of 
photosensitizers was first proposed by Mew and co-workers in 
the 1980s,2 with minor advancements achieved throughout 
the next few decades. However, in recent years, there has 
been somewhat of a re-birth in the area, particularly due to 
developments in antibody targeting (i.e. to distinguish 
between cancerous and non-cancerous cells) and the FDA-
approval of several antibody-drug conjugates (ADCs).1,3 
Conceptually, by attaching photosensitizers to cancer cell 
directed antibodies and injecting them into suitable cancer 
patients that have a cancer which overexpresses an 
appropriate antibody receptor, there will be selective delivery 
of the photosensitizers to cancerous tissue. Irradiation of the 
tumour will then activate the photosensitizers and induce the 
formation of reactive oxygen species (ROS), which will effect 
cell death. The destruction of cells by this method has been 
shown to destroy tumours by various mechanisms of action, 
however, they are all mediated by ROS generation.4 This 
provides an important additional level of selectivity over 
conventional antibody-drug conjugates, i.e. the drug is only 
activated upon irradiation. Thus, targeted PDT has great 
potential to eliminate highly undesirable off-target toxicity, 
which is a major issue in existing chemotherapy and results in 
a low therapeutic ceiling for ADCs where the active cytotoxic 
drugs are delivered off-site due to issues of imperfect antibody 
targeting and poor drug-linker stability in serum.1,3,5 
 Whilst the concept of targeted PDT using monoclonal 
antibodies is undoubtedly very attractive, the delivery of a 
suitable platform to realise the true potential of this concept 
has lagged behind.1 For targeted PDT, conjugation to 
antibodies is typically achieved through multiple lysine 
modification. Lysine modification is suboptimal as it generates 
heterogeneous products, which can result in batch-to-batch 
variability and poor pharmacokinetics.6 Cysteine modification, 
following inter-chain disulfide reduction is another viable 
strategy, however this results in the permanent loss of 
structural disulfide bonds, which may reduce the stability of 
the antibody conjugate in vivo.6 Moreover, cysteine 
modification is often carried out by reaction with classical 
maleimide compounds. Whilst this reaction is reliable, it has 
been widely reported (and unequivocally proven) that the 
formed succinimide conjugate is unstable in serum.5,7a This is 
due to the propensity of this motif to undergo retro-conjugate 
addition. This subsequently leads to undesirable transfer of 
the attached cargo onto blood thiols, particularly human 
serum albumin, thus resulting in off-target delivery.5,7a 
 Recently, we have described a site-selective method for 
the insertion of a dibromomaleimide into the disulfide bond of 
a fragment antigen-binding (Fab) arm of trastuzumab, a 
clinically approved antibody for the treatment of breast 
cancer.8 Whilst this study provided proof of concept for site-
selective porphyrin attachment to an antibody fragment, 
several shortcomings have come to light: (i) use of a Fab 
fragment with a single disulfide bond limits porphyrin 
attachment to one; (ii) dithiomaleimides (without hydrolysis) 
have been shown to be unstable in blood serum;7b (iii) access 
to the Fab fragment of trastuzumab through bacterial 
expression is not facile; and (iv) a copper-based “click” 
procedure necessitates prior porphyrin metalation (e.g. Zn) to 
prevent loss of both therapeutic singlet oxygen generation and 
fluorescent properties caused by copper insertion into the 
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central cavity – this results in a blue shift of porphyrin light 
absorption, which is clinically undesirable.9 Herein, we 
overcome all of the issues by providing a copper-free “click” 
method for the site-selective decoration of an antibody with 
serum stable linkers and an improved porphyrin loading of 
four. 
 Initially we needed to select a suitable biomolecule that 
would allow for higher porphyrin loading, as well as still using a 
technology that allowed for site-selective modification. To this 
this end, we choose to use IgG trastuzumab in view of its 
clinical validation alone, as the antibody component of FDA-
approved ADC Kadcyla™ and as it contains four disulfides for 
site-selective functionalisation.7b,10,11a Following this, we 
considered what disulfide linker technology should be applied 
for modification of the IgG. Chudasama, Caddick and 
co-workers have recently shown dibromopyrdazinediones to 
be viable candidates for disulfide stapling and that the 
resulting bisthioether is stable in blood plasma mimicking 
conditions.11 As such, we chose this entity for functional 
disulfide bridging. Finally, to make our new platform modular 
and amenable to the use of copper-free “click” chemistry, a 
strained alkyne moiety was to be appended to the 
dibromopyrdazinedione, to allow for a copper-free strain-
promoted alkyne-azide cycloaddition (SPAAC) reaction with a 
porphyrin azide.  
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Scheme 1 Synthesis of dibromopyrdazinedione-strained alkyne 6.
Reagents and Conditions: (i) Boc2O, NEt3, DMAP, CH2Cl2, 21 °C, 16 h; (ii) 
Mg(ClO4)2, MeCN, 50 °C, 1 h; (iii) tert-butyl bromoacetate, Cs2CO3, 
DMF, 21 °C, 16 h; (iv) TFA, CH2Cl2, 21 °C, 30 min; (v) dibromomaleic 
anhydride, AcOH, 21 °C for 16 h, then reflux, 2 h; (vi) PyBOP, DIPEA, 
CH2Cl2, 21 °C, 16 h. 
 Our study began with the synthesis of a suitable 
dibromopyrdazinedione-strained alkyne (Scheme 1). Initially, 
inexpensive methylhydrazine 1 was fully Boc protected to give 
hydrazine 2 in >99% yield. Following a procedure by Stafford et 
al., hydrazine 2 was selectively mono-deprotected by mild 
cleavage of one of the Boc groups, using Mg(ClO4)2 catalysis, to 
yield mono-protected hydrazine 3,12 which was then alkylated 
to give tert-butyl ester 4 in 87% yield over the three steps. 
Hydrazine-ester 4 was then deprotected and condensed with 
dibromomaleic anhydride to afford acid-bearing 
pyridazinedione 5 in 73% yield. Finally, PyBOP-mediated 
coupling between commercially available BCN−PEG2−NH2 and 
acid 5 afforded bicyclononyne-based Methyl-Strained Alkyne 
PD 6 (Mestra PD) in 54% yield. 
 We next appraised whether dibromopyrdazinedione-
strained alkyne 6 was amenable for the functional re-bridging 
of the disulfides of trastuzumab 7. To do this, TCEP was added 
to a solution of trastuzumab in borate buffered saline (pH 8.0), 
containing an excess of Mestra PD 6, and the mixture 
incubated at 4 °C for 16 h. Gratifyingly, analysis by SDS-PAGE 
revealed formation of Mestra-trastuzumab conjugate 8. The 
number of pyrdazinediones per antibody was appraised by UV-
Vis and was found to be four, which is consistent with 
complete re-bridging of the four accessible disulfides of 
trastuzumab.11a
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Scheme 2 Insertion of dibromopyrdazinedione-strained alkyne 6 into 
the four disulfide bonds of trastuzumab 7 to form conjugate 8. 
 Following on from the successful synthesis of conjugate 8, 
we set about synthesising water soluble porphyrin azide 9. 
This porphyrin is ideal as a therapeutic agent as the cationic 
tripyridinium motif provides excellent hydrophilicity without 
the toxicity associated with sulfonate derivatives.8 The azide 
PEG chain also allows for facile “click” conjugation whilst also 
reducing steric hindrance between the porphyrin and antibody 
conjugate. In comparison to its previously employed zinc 
metallated counterpart, free base derivative 9 has more 
favourable photophysical properties; most significantly, a large 
(ca. 40 nm) red shift in the highest wavelength Q-band. This 
increase in absorption at longer wavelengths allows for 
enhanced tissue penetration by light, and thus, increased 
clinical relevance. Synthesis of porphyrin azide 9 was carried 
out according to the procedure described by Bryden et al.,8 
excluding the zinc metalation step.  
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Figure 1 Structure of water soluble porphyrin azide 9. 
 Following the successful synthesis of azide 9, it was reacted 
with Mestra-trastuzumab conjugate 8 using SPAAC chemistry. 
The optimised conditions, incubation of conjugate 8 with 5 
equivalents of the porphyrin azide for 4 h at 37 °C, effected 
complete conversion to conjugate 10 in near quantitative yield 
and in high purity. Porphyrin loading was confirmed by UV-Vis 
and optimisation of the reaction conditions was carried out on 
the Fab arm of trastuzumab (see ESI for details).  
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Figure 2 Structure of trastuzumab porphyrin conjugate 10. 
 With trastuzumab-porphyrin conjugate 10 in hand we next 
appraised its efficacy in vitro, with trastuzumab only as a 
control, using appropriate HER2+ and HER2- cell lines (i.e. BT-
474 and MDA-MB-468, respectively). To do this, experiments 
were carried out as described in the ESI. In these experiments, 
broad spectrum light (20 J cm-2) was used to ensure sufficient 
activation of the photosensitizer from the QTH lamp used. 
Clinically, light in the red region of the spectrum would more 
typically be used, where the weaker absorption of the 
porphyrins in this region is compensated for by using 
biomedical lasers with light fluences which are orders of 
magnitude greater than those used here. The present study 
was thus designed to assess photodynamic potential in vitro, 
and further studies using red light would clearly be needed 
before moving to a clinical setting. 
 Under the tested conditions, it can unambiguously be seen 
that conjugate 10 exhibits remarkable abilities to eradicate 
HER2+ cells (ca. 90% kill), while at the same concentration 
leaving HER2- cells unaffected (Figure 3). In both cell lines, 
conjugate 10 displayed minimal dark toxicity at the highest 
antibody concentration used (3 μM) and no dark toxicity at the 
concentration required to kill 90% of cells on irradiation 
(625 nM). 
Control experiments using trastuzumab alone or unconjugated 
porphyrin 9 (Full data in ESI) showed no cytotoxicity for the 
antibody and minimal cytotoxicity (< 80%) for the 
unconjugated porphyrin with both cell lines at the 
concentration where 90% of cells were killed by the conjugate 
(625 nM). 
Figure 3 In vitro appraisal of trastuzumab porphyrin conjugate 10 and 
trastuzumab alone in broad spectrum light at an antibody 
concentration of 625 nM (Full cytotoxicity data in ESI). 
Conclusions 
In conclusion, we have provided an important step towards 
delivering on next-generation antibody-based porphyrin 
conjugates. In this manuscript we site-selectively modify a full 
antibody with four pyrdazinedione linkers (one per native 
disulfide), each bearing a strained alkyne handle, in a 
controlled manner. Following this, facile SPAAC chemistry was 
performed to provide a defined multi-porphyrin antibody 
conjugate, which was shown to be active in vitro.  
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